Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 74
Filter
1.
Article in Chinese | WPRIM | ID: wpr-880048

ABSTRACT

OBJECTIVE@#To explore the expression of CD40/CD40L in multiple myeloma(MM) patients and its influence on prognosis.@*METHODS@#Thirty patients with MM treated in Cangzhou People's Hospital from May 2016 to June 2017 were selected and divided into MM group, then 30 healthy people with a physical examination in our hospital at the same time were selected as the normal group. The serum CD40/CD40L levels of the patients in the two groups was detected by flow cytometry, and its correlation with the lymphocyte population, pathological grade and prognostic significance of MM patients was anaysis.@*RESULTS@#The expression of CD40 in serum of the patients in MM group was significantly higher than those in normal group (P0.05). The levels of CD40 and CD40L in the patients before and after chemotherapy showed no difference(P>0.05). The levels of Ts and NK cells in the patients of MM group were lower than those in normal group (P0.05). The CD40 level was correlated with the serum total B lymphocyte level of the patients in MM group (r=0.877, P=0.005). There was a correlation with CD40L and Th cells in the serum of MM patients (r=-0.783, P=0.035). The expression of serum CD40 in the patients at phase III-IV was higher than those of the patients at phase I-II, the levels of serum CD40L in MM patients at different periods showed no significant difference(P>0.05). The survival rate of MM patients with high CD40 expression was lower than that of MM patients with low CD40 expression (χ@*CONCLUSION@#The increasing of CD40 level in MM patients is related to the pathological grade of the patients. Chemotherapy can reduce the level of CD40. The increasing of CD40 is an important factor for the poor prognosis of MM patients. CD40L level is not meaningful for MM treatment and prognosis.


Subject(s)
Humans , B-Lymphocytes , CD40 Antigens , CD40 Ligand , Lymphocyte Subsets , Prognosis
2.
São Paulo; s.n; 2020. 81 p. ilust, tabelas.
Thesis in Portuguese | LILACS, Inca | ID: biblio-1178924

ABSTRACT

Introdução: O mieloma múltiplo é uma desordem clonal das células plasmocitárias e, responde por 10-15% das neoplasias hematológicas. Apresenta diversas alterações no sistema imune, caracterizadas por déficits na produção de anticorpos; alterações do perfil imunológico das células T; aumento da expressão do PD-L1; modificações no microambiente medular favorecendo o recrutamento de populações imunossupressoras como as Treg e disfunção nas células dendríticas. Manter um sistema imune ativo é fundamental para o controle da doença, pacientes com manutenção de células T efetoras apresentam maiores taxas de remissão e sobrevida. Receptores coestimuladores como o OX40, CD40/CD40L e 4-1BB, participam na ativação, proliferação e amplificação da resposta imune. Objetivo: Avaliar os níveis de linfócitos B e T e das moléculas coestimuladoras OX40, CD40, CD40L e 4-1BB no sangue e medula óssea dos pacientes com mieloma múltiplo. Métodos: Trata-se de estudo exploratório, realizado entre 2016 e 2019 no Hospital de Câncer de Pernambuco (HCP) e Laboratório de Pesquisa Translacional do Instituto de Medicina Integral Prof. Fernando Figueira (IMIP). Foram incluídas 40 pacientes, até 79 anos de idade, com diagnóstico de Mieloma Múltiplo. Coletas de sangue periférico e medula óssea foram realizadas ao diagnóstico. As mensurações dos níveis de expressão de proteínas de membrana CD20, CD3, OX40, CD40/CD40L foram detectadas pela técnica de Cytometric Bead Array por citometria de fluxo. A dosagem dos níveis solúveis de s4-1BB, sOX40 e sCD40L foi realizada por enzyme linked immunonoSorbent assay (ELISA). Foi realizada análise de curva Receiver Operating Characteristic (ROC) para determinar o melhor valor de acurácia de cada marcador estudado assim como, a ocorrência de óbito. A análise estatística foi realizada no programa GraphPadPrism v8.0. O nível de significância estatística foi de p<0,05. Resultados: Em sangue periférico, comparando-se pacientes e controles, verificou-se níveis menores de CD20 (p<0,0001) e CD20low (p<0,0001), CD40+ em leucócitos totais (p=0,0005), CD40+ em linfócitos (0,0006) e CD40/CD3+ (p<0,0001) no grupo de pacientes. Mas, em contrapartida, os pacientes apresentaram níveis mais elevados de OX40+ (p=0,0012), CD40L+ em leucócitos totais (p=0,002) e OX40+/CD3+ (p<0,0001). Os níveis séricos de s4-1BB (p=0,03) e sOX40 (p=0,01) estavam reduzidos no grupo de MM quando comparado aos controles. Na análise segundo o ISS, somente os níveis de expressão de CD40L+ em leucócitos (p=0,01) e de CD40+ em linfócitos (p=0,0045), mostraram níveis superiores nos pacientes com ISS1-2 em relação ao ISS-3. As medidas de expressão de OX40+ e CD40L+ em leucócitos totais eram inferiores nos casos com evolução para óbito (p<0,0006 e p=0,002, respectivamente). Os pacientes que apresentavam níveis de expressão de OX40 em leucócitos totais ≥2,93% tiveram maior sobrevida em relação àqueles com valores <2,93% (p=0,03), bem como aqueles com CD40L em leucócitos totais com valores ≥3,09% (p=0,001). Na análise da medula óssea, segundo o ISS, somente os níveis de expressão de OX40/CD3+, mostraram níveis superiores nos pacientes com ISS1-2 em relação ao ISS-3 (p<0,0017). Não foram observadas diferenças significativas entre os valores de expressão dos diversos marcadores em medula óssea, com relação ao desfecho óbito. Na análise de correlação de Spearman, os valores de CD20 em sangue e medula óssea, apresentam uma correlação moderada entre si (r=0,64 e p<0,0001). Conclusão: Os resultados deste estudo permitem concluir que existem alterações de mecanismos celulares envolvidos na regulação e ativação da resposta imune no MM quando comparados aos controles. A manutenção de níveis mais elevados de moléculas coestimuladoras (OX40 ≥2,93% e CD40L≥ 3,09%), foi preditiva de melhor sobrevida no MM


Introduction: Multiple myeloma (MM) is a malignant plasma cell (PC) disorder, accounting for approximately 10-15% of all hematological cancers. Multiple myeloma presents several immune system alterations, characterized by deficits in antibody production, disruption of the T-cell immune profile, increased expression of cell death ligand 1 (PD-L1), changes in the bone marrow microenvironment favoring the recruitment of immunosuppressive populations such as Tregs and dysfunction in dendritic cells. It is important to preserve the integrity of the active immune system for the control of disease progression and patients with maintenance of T-cell cytotoxic activities improve rates of remission and overall survival. Co-stimulating receptors such as OX40, CD40/CD40L and 4-1BB, cooperate in the activation, proliferation, and amplification of the immune response. Objective: To evaluate T and B lymphocyte levels as well as co-stimulating molecules OX40, CD40, CD40L and 4-1BB in the blood and bone marrow of multiple myeloma patients. Methods: This is a cross-sectional and exploratory study, conducted between 2016 and 2019 at Pernambuco Cancer Hospital (HCP) and Translational Research Laboratory of Instituto de Medicina Integral Prof. Fernando Figueira (IMIP). Forty patients, up to 79 years of age, diagnosed with Multiple Myeloma were included. Peripheral blood and bone marrow samples were collected at diagnosis. Serum concentrations of CD20, CD3, OX40, CD40/CD40L were detected through the Cytometric Bead Array technique by flow cytometry, and the soluble forms of s4-1BB, sOX40 e sCD40L by enzyme linked immunosorbent assays. Receiver Operating Characteristic (ROC) curve analysis was performed to determine not only the best accuracy value of each studied marker but also, mortality. Statistical analysis was performed in the GraphPadPrism v8.0 program and the level of statistical significance was p <0.05. Results: In peripheral blood, comparing patients and controls, there were lower levels of CD20 (p<0.0001) and CD20low (p<0.0001), CD40+ in total leukocytes (p=0.0005), CD40+ in lymphocytes (0.0006) and CD40/CD3+ (p<0.0001) in the patient group. However, on the other hand, patients had higher levels of OX40+ (p=0.0012), CD40L+ in total leukocytes (p=0.002) and OX40+/CD3+ (p<0.0001). Serum levels of s4-1BB (p=0.03) and sOX40 (p=0.01) were reduced in the MM group compared to controls. According to the ISS, CD40L+ in leukocytes (p=0.01) and CD40+ in lymphocytes (p=0.0045) showed higher levels in patients with ISS1-2 compared to ISS-3. Regarding the outcome death, levels of OX40+ and CD40L+ in total leukocytes were lower (p<0.0006 and p=0.002, respectively). In survival analyses, patients who had OX40+ levels in total leukocytes ≥2.93% had higher survival compared to those with levels <2.93% (p=0.03), as well as those with CD40L+ in total leukocytes with values ≥3.09% (p=0.001). In the bone marrow only the OX40/CD3+ levels were higher in patients with ISS1-2 compared to ISS-3 (p<0.0017). No significant differences were observed between values of other bone marrow markers in relation to the outcome death. In Spearman's correlation analysis, CD20 levels in blood and bone marrow present moderate correlation between them (r=0.64 and p<0.0001). Conclusion: This study shows differences in cellular mechanisms involved in the regulation and activation of immune response in MM patients in comparison to healthy controls. The maintenance of higher levels of co-stimulating molecules (OX40 ≥2.93% and CD40L≥ 3.09%) is associated with better survival in multiple myeloma


Subject(s)
Humans , Male , Female , Middle Aged , Aged , CD40 Antigens , CD40 Ligand , Tumor Necrosis Factor Receptor Superfamily, Member 9 , Receptors, OX40 , Multiple Myeloma
3.
Braz. j. med. biol. res ; 50(6): e6227, 2017. graf
Article in English | LILACS | ID: biblio-839309

ABSTRACT

Adiponectin is a multifunctional adipokine that has several oligomeric forms in the blood stream, which broadly regulates innate and acquired immunity. Therefore, in this study, we aimed to observe the differentiation of T helper (Th) cells and expression of costimulatory signaling molecules affected by adiponectin. The mRNA and protein expression levels of adiponectin and its receptors in oxidized low density lipoprotein cholesterol-treated endothelial cells were assayed by real time PCR and immunofluorescence. The endothelial cells were then treated with adiponectin with or without adipoR1 or adipoR2 siRNA and co-cultured with T lymphocytes. The distribution of Th1, Th2 and Th17 subsets were assayed by flow cytometry. The effects of adiponectin on costimulatory signaling molecules HLA-DR, CD80, CD86 and CD 40 was also assayed by flow cytometry. The results showed that endothelial cells expressed adiponectin and its receptor adipoR1 and adipoR2, but not T-cadherin. Adiponectin suppressed Th1 and Th17 differentiation through adipoR1 receptor, contributed to the inhibition of CD80 and CD40, and inhibited differentiation of Th1 and Th17 by inhibiting antigen presenting action.


Subject(s)
Humans , Infant, Newborn , Adult , Adiponectin/metabolism , B7-1 Antigen/metabolism , CD40 Antigens/metabolism , T-Lymphocytes, Helper-Inducer/drug effects , Adiponectin/genetics , Adiponectin/pharmacology , Cell Differentiation , Cells, Cultured , Endothelial Cells/drug effects , Endothelial Cells/metabolism , HLA-DR Antigens/metabolism , Human Umbilical Vein Endothelial Cells/cytology , Lipoproteins, LDL/pharmacology , Receptors, Adiponectin/drug effects , Receptors, Adiponectin/metabolism , T-Lymphocytes, Helper-Inducer/cytology , T-Lymphocytes, Helper-Inducer/metabolism
4.
Article in Chinese | WPRIM | ID: wpr-296595

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the association of SNP of CD40 gene and its serum levels with ischemic stroke (IS).</p><p><b>METHODS</b>A total of 202 IS patients from a hospital of Baise city were enrolled in case group from May 2013 to November 2014. At the same time, 109 healthy people who had physical check-ups in the outpatient department at the same hospital were enrolled in the control group. All participants were from Guangxi Zhuang Autonomous Region and unrelated to each other. 3 ml venous blood were collected on the premise of informed consent. The single nucleotide polymorphisms of CD40 gene rs1883832 C/T, rs13040307 C/T, rs752118 C/T and rs3765459 G/A were analyzed using a Snapshot SNP genotyping assays, and the serum levels of CD40 were tested by ELISA. t-test was used to compare the serum levels of CD40 between the case and control group, and the genotypes at different locuses in case group; χ(2) test was used to compare the distribution differences of the CD40 gene locuses in different genotypes and allele between the case group and the control group; alleles was established as independent variables, the occurrence of the IS as dependent variable, and expressed relative risk with OR (95%CI) value.</p><p><b>RESULTS</b>In the case group, the frequency of CC, CT and TT genotypes in CD40 gene rs1883832 C/T were 21.78% (44/202), 49.51% (100/202) and 28.71% (58/202), respectively, and 33.17% (66/199), 48.74% (97/199), 18.09% (36/199) in the control group, respectively, the differences between the two groups was significant (χ(2)=9.57, P=0.008). The CD40 serum levels were (62.7 ± 24.5) pg/ml in the case group, which was higher than that in the control group (45.3 ± 17.2) pg/ml (t=8.97, P<0.001). The serum levels of TT and CT genotypes in CD40 gene were (65.9 ± 26.3) and (64.3 ± 25.9) pg/ml, respectively, and the differences were significant when comparing with CC genotype (t equaled 5.34 and 5.03, respectively, P<0.001). The risk of developing IS was 1.56 times higher in 1883832 T allele carriers than that in rs1883832 C allele carriers (OR=1.56, 95% CI: 1.18-2.06); Combined genotype analysis displayed that CD40 gene rs1883832 C/T, rs13040307 C/T, rs752118 C/T and rs3765459 G/A polymorphisms showed strong linkage disequilibrium, the case group TCCA haplotype was tested to be associated with a significantly increased risk of IS as compared with that in the control group(OR=2.49; 95%CI: 1.13-5.48).</p><p><b>CONCLUSION</b>CD40 gene rs1883832 C/T polymorphism and its TCCA haplotype were possibly associated with ischemic stroke, and the susceptibility gene for ischemic stroke may be rs1883832 T allele.</p>


Subject(s)
Humans , Alleles , CD40 Antigens , Blood , Genetics , Case-Control Studies , Cell Differentiation , China , Gene Frequency , Genetic Predisposition to Disease , Genotype , Haplotypes , Polymorphism, Single Nucleotide , Stroke , Blood , Genetics
5.
Article in English | WPRIM | ID: wpr-23360

ABSTRACT

PURPOSE: The aim of this study was to assess the expressions of CD44 and CD133 in colorectal cancer tissue by using immunohistochemical staining and to analyze the clinical significance of the expressions related to other clinicopathological data and survival results. METHODS: One hundred sixty-two patients with a biopsy-proven colorectal adenocarcinoma who were operated on between January 1998 and August 2004 were enrolled in this study. Immunohistochemical staining for CD44 and CD133 was performed on primary colorectal cancer tissue, metastatic lymph nodes, and synchronous and metachronous metastatic tumor tissues if available. RESULTS: CD44 expression was stronger in the primary tumor than in metastatic lymph nodes (P < 0.001), and CD133 expression tended to be stronger in primary tumor than in metastatic lymph nodes (P = 0.057). No significant correlation was found between the CD44 and the CD133 expressions. The cases with recurrence showed low expression of CD44 (P = 0.017). CD133 expression was lower in cases with elevated CA 19-9 serum levels (P = 0.028) and advanced T stage (P = 0.038). Multivariate analysis proved that low expression of CD44 was an independent prognosis factor for short disease-free survival (P = 0.028). CONCLUSION: Low CD44 expression was correlated with increased tumor recurrence and short disease-free survival, and low CD133 expression was associated with advanced tumor stage. We suggest that further studies be performed to evaluate whether the immunohistochemical method for determining the CD44 and the CD133 expressions is appropriate for exploring cancer stem-cell biology in patients with colorectal cancer.


Subject(s)
Humans , Adenocarcinoma , CD40 Antigens , Biology , Colorectal Neoplasms , Disease-Free Survival , Lymph Nodes , Multivariate Analysis , Neoplastic Stem Cells , Prognosis , Recurrence , Stem Cells
6.
Article in English | WPRIM | ID: wpr-76933

ABSTRACT

BACKGROUND: Anti-Gal is a major antibody induced in non-human primates (NHPs) after xenotransplantation. To understand the mechanism of graft rejection, we investigated the association between anti-Gal responses and graft failure in NHP recipients of porcine islet transplantation (PITx). METHODS: Intraportal PITx was performed in 35 diabetic NHPs, and graft function was monitored. Early graft failure (EGF) was defined as loss of graft function within a month after PITx. Seven, 19, nine NHPs received immunosuppression (IS) without CD40 pathway blockade (Group I), with anti-CD154 (Group II), and with anti-CD40 (Group III), respectively. The anti-Gal levels on day 0 and day 7 of PITx were measured by ELISA. RESULTS: The frequency of EGF was significantly lower in Group II (26.3%) than in Group I (100%, P=0.0012) and Group III (77.8%, P=0.0166). While levels of anti-Gal IgG in Group I and anti-Gal IgM in Group III increased on day 7 compared with day 0 (P=0.0156 and 0.0273), there was no increase in either on day 7 in Group II. The ratio of anti-Gal IgM or IgG level on day 7 to that on day 0 (Ratio7/0) was significantly higher in recipients with EGF than without EGF (P=0.0009 and 0.0027). ROC curve analysis of anti-Gal IgM Ratio7/0 revealed an area under the curve of 0.789 (P=0.0003). CONCLUSIONS: IS with anti-CD154 suppressed anti-Gal responses and prevented EGF in PITx. Anti-Gal IgM Ratio7/0, being associated with EGF, is a predictive marker for EGF.


Subject(s)
Animals , Antibodies/blood , CD40 Antigens/immunology , Area Under Curve , CD40 Ligand/immunology , Disaccharides/immunology , Epidermal Growth Factor/blood , Graft Rejection/immunology , Immunoglobulin G/blood , Immunoglobulin M/blood , Immunosuppressive Agents/therapeutic use , Islets of Langerhans Transplantation , Macaca mulatta , ROC Curve , Swine , Transplantation, Heterologous
7.
Article in Chinese | WPRIM | ID: wpr-815279

ABSTRACT

OBJECTIVE@#To investigate the expression of inflammatory molecule CD40 in the pallium and hippocampus of rats after status epilepticus (SE).
@*METHODS@#The expression of CD40 in the pallium, the different areas of hippocampus and the different cells from the lithium-pilocarpine epileptic rats at different time points were examined by immunohistochemistry and double-immunofluorescent labeling.
@*RESULTS@#After SE, CD40 expression was obviously inhibited, especially in hippocampus. CD40 was mainly expressed in the activated microglia. CD40 positive cells reached a peak at the 3rd day and returned to a slightly higher level at the 7th day after SE compared with the level before SE.
@*CONCLUSION@#Elevation of CD40 expression in the activated microglia can promote inflammatory injury of rat's hippocampus, suggesting that CD40 induced-signal pathway is involved in inflammatory injury in the hippocampus after SE.


Subject(s)
Animals , Rats , CD40 Antigens , Metabolism , Epilepsy , Hippocampus , Metabolism , Immunohistochemistry , Lithium , Microglia , Metabolism , Pilocarpine , Rats, Sprague-Dawley , Status Epilepticus
8.
Article in English | WPRIM | ID: wpr-812533

ABSTRACT

The aim of the study was to investigate the anti-asthmatic effects of oxymatrine (OXY) and the possible underlying mechanisms. The mouse asthma model was established by ovalbumin (OVA) intraperitoneal injection. A total of fifty mice were randomly assigned to five groups: control, OVA, OVA + dexamethasone (Dex, 2 mg · kg(-1)), and OVA + OXY (40 mg · kg(-1)), and OVA + OXY (80 mg · kg(-1)), respectively. Histological studies were conducted by the hematoxylin and eosin (HE) staining, the levels of interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-13, and IgE were evaluated by enzyme-linked immunosorbent assay (ELISA), and the protein level of CD40 was analyzed by Western blotting. OXY inhibited OVA-induced increases in eosinophil count; the levels of IL-4, IL-5, IgE, and IL-13 were recovered. It also substantially inhibited OVA-induced eosinophilia in lung tissues and the expression of CD40 protein. These findings suggest that OXY may effectively ameliorate the progression of asthma and could be explored as a possible therapy for patients with allergic asthma.


Subject(s)
Animals , Female , Alkaloids , Pharmacology , Anti-Asthmatic Agents , Pharmacology , Anti-Inflammatory Agents , Pharmacology , Asthma , Drug Therapy , Bronchoalveolar Lavage Fluid , Chemistry , CD40 Antigens , Metabolism , Dexamethasone , Pharmacology , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Immunoglobulin E , Metabolism , Interleukins , Metabolism , Irritants , Toxicity , Mice, Inbred BALB C , Ovalbumin , Toxicity , Pulmonary Eosinophilia , Drug Therapy , Quinolizines , Pharmacology , Random Allocation , Signal Transduction
9.
Article in Chinese | WPRIM | ID: wpr-279079

ABSTRACT

<p><b>OBJECTIVE</b>To study the frequency distribution of single nucleotide polymorphisms (SNPs) in two genes associated with incomplete Kawasaki disease (KD) (rs1569723 in CD40 gene and rs2736340 in BLK gene), and to investigate its association with the genetic susceptibility and clinical phenotypes of incomplete KD.</p><p><b>METHODS</b>A total of 184 children with incomplete KD and 203 normal children were recruited to carry out a case-control study. The genotypes of SNPs in CD40 gene and BLK gene were determined using polymerase chain reaction-restriction fragment length polymorphism. The frequency distribution of genotypes was compared between the KD and control groups. The association between gene polymorphisms and clinical features of incomplete KD was analyzed.</p><p><b>RESULTS</b>There were no significant differences in genotype (AA, AC, CC) and allele frequencies in CD40 SNP rs1569723 between the KD and control groups. There were significant differences in the frequency distribution of three genotypes (TT, CT, CC) in BLK SNP rs2736340 between the KD and control groups (P=0.031), and the KD group had a significantly higher frequency of T allele than the control group (P=0.007). There were significant differences in the incidence of conjunctival hyperaemia among the patients with different genotypes (rs1569723 in CD40 gene) (P=0.036). The SNP rs2736340 in BLK gene was associated with the extremity changes in KD patients (P=0.017).</p><p><b>CONCLUSIONS</b>The SNP rs2736340 in BLK gene is associated with the susceptibility to incomplete KD, and the SNP rs1569723 in CD40 gene and SNP rs2736340 in BLK gene are associated with some of clinical phenotypes of incomplete KD.</p>


Subject(s)
Child , Child, Preschool , Female , Humans , Infant , Male , CD40 Antigens , Genetics , Genetic Predisposition to Disease , Mucocutaneous Lymph Node Syndrome , Genetics , Polymorphism, Single Nucleotide
10.
Article in Chinese | WPRIM | ID: wpr-297458

ABSTRACT

<p><b>OBJECTIVE</b>To study whether co-stimulatory molecule CD40 of alveolar macrophage (AM) participated in the occurrence and development of silicosis, and to explore the intervention of Yiqi Huoxue Decoction (YHD) in the fibrosis of silicosis patients.</p><p><b>METHODS</b>Totally 46 silicosis inpatients and outpatients were recruited and randomly assigned to the Western treatment group (A) and the Chinese medicine (CM) treatment group (B), 23 in each group. Patients in Group A received routine symptomatic treatment such as anti-inflammation, phlegm resolving, anti-spasm, and asthma relief, and so on. Patients in Group B additionally took YHD, one dose daily for 14 successive days. Besides, another 18 patients with chronic cough and sense of laryngeal foreign bodies were recruited as the normal control group, who had no obvious lesion confirmed by bronchofi6roscope and clinical diagnosis of the lung. They were treated by symptomatic supporting treatment. The alveolar lavage fluid was collected from all patients and isolated, and AM cells were cultured. The level of CD40 mRNA was detected by RT-PCR. The expression of CD40 protein was detected by Western blot.</p><p><b>RESULTS</b>Compared with the normal control group, expression levels of CD40 mRNA and CD40 protein significantly increased in Group A (P < 0.01). Compared with Group A, expression levels of CD40 mRNA and CD40 protein significantly decreased in Group B (P < 0.01).</p><p><b>CONCLUSIONS</b>Highly expressed co-stimulatory molecule CD40 of AM might participate in pulmonary fibrosis. YHD could hinder its roles, inhibit the progression of fibrosis, thereby playing an interventional role of treatment.</p>


Subject(s)
Humans , Male , CD40 Antigens , Metabolism , Drugs, Chinese Herbal , Therapeutic Uses , Fibrosis , Lung , Pulmonary Fibrosis , RNA, Messenger , Metabolism , Silicosis , Drug Therapy , Metabolism
11.
Article in Chinese | WPRIM | ID: wpr-232521

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the role of glycogen synthase kinase 3β (GSK-3β) in the maturation and function of murine bone marrow-derived dendritic cells (BMDCs).</p><p><b>METHODS</b>Mature DCs (mDCs) induced by LPS were examined for GSK-3β phosphorylation level with Western blotting before and after LPS exposure. To explore the role of GSK-3β in maturation and function of DCs, we added SB216763, a selective inhibitor of GSK-3β, in the cell culture of immature DCs (iDCs), and examined CD40 and CD86 expressions in the cells by flow cytometry and the expression of IL-6, IL-12 and IL-10 mRNA by real-time PCR; the changes of the immunogenicity of the cells was evaluated by mixed lymphocyte reaction. The expression of GSK-3β and RelB was examined by Western blotting in DC2.4 cells transfected with a lentiviral vector over-expressing murine GSK-3β gene.</p><p><b>RESULTS</b>LPS exposure significantly lowered GSK-3β activity in iDCs as demonstrated by increased Ser9 phosphorylation and reduced Tyr216 phosphorylation. GSK-3β inhibition induced DC maturation by increasing the expression of surface costimulatory molecules CD40 and CD86, lowered the expressions of IL-6 and IL-12 while enhanced the expression of IL-10 in iDCs, and impaired mixed lymphocyte reaction of the cells. In DC2.4 cells, lentivirus-mediated over-expression of GSK-3β obviously down-regulated the expression of RelB.</p><p><b>CONCLUSIONS</b>GSK-3β is a crucial enzyme involved in the differentiation and maintenance of an immature phenotype of DCs. GSK-3β is constitutively active in iDCs to inhibit their spontaneous maturation. DCs become phenotypically mature after inhibition of GSK-3β, which also executes a proinflammatory task in DC activation. The reduction of RelB protein levels as a result of GSK-3β overexpression supports GSK-3β as a new target for inducing tolerogenic DCs.</p>


Subject(s)
Animals , Mice , B7-2 Antigen , Metabolism , CD40 Antigens , Metabolism , Cell Differentiation , Cells, Cultured , Culture Media , Chemistry , Dendritic Cells , Glycogen Synthase Kinase 3 , Metabolism , Glycogen Synthase Kinase 3 beta , Indoles , Chemistry , Interleukin-10 , Metabolism , Interleukin-12 , Metabolism , Interleukin-6 , Metabolism , Lentivirus , Lymphocyte Culture Test, Mixed , Maleimides , Chemistry , Myeloid Cells , Phosphorylation , RNA, Messenger , Real-Time Polymerase Chain Reaction , Signal Transduction
12.
Article in Chinese | WPRIM | ID: wpr-302396

ABSTRACT

This study was aimed to explore the effects of blocking B7/CD28 and CD40/CD154 co-stimulatory signals on immune function of sensitized mice', and provide the evidences of acquired immune tolerance for allogeneic bone marrow transplantation. The mice sensitized on 7 day before transplant were divided into 4 groups: (1)CTLA4Ig+ anti-CD154 isotype control IgG; (2)anti-CD154 +CTLA4Ig isotype control IgG; (3)CTLA4Ig and anti-CD154; (4)isotype control IgG of CTLA4Ig and anti-CD154. CTLA4Ig and anti-CD154 used in normal BALB/c mice as isotype control IgG. Each mouse in all groups received CTLA4Ig and anti-CD154 (or corresponding isotype control IgG) 500 µg respectively, and was injected via tail vein on 7 day before transplant. There were 5 mice in each group. The mice were sacrificed on day 0, then the number of CD19(+)CD69(+)B cells, CD44(high)/CD62L(high) and CD44(high)/CD62L(low)/- T cells were measured by flow cytometry. Changes of cytokines and sensitized antibody were tested by ELISA or flow cytometry. The results showed that the numbers of CD19(+)CD69(+)B cells were significantly increased in comparison with the normal group (P < 0.01) , whereas the numbers of cells were significantly decreased when blocking B7/CD28 or /and CD40/CD154 co-stimulatory signals (P < 0.01) . Blocking these 2 signals together displayed a synergistic effect (P < 0.01) . The central memory and effector T cells were defined as CD44(high)/CD62L(high) and CD44(high)/CD62L(low)/- respectively, those increased significantly after sensitized in comparison with those in normal group, whereas their numbers decreased when blocking B7/CD28 or/and CD40/CD154 co-stimulatory signals. Blocking these two signals together, displayed a synergistic effect (P < 0.01). Cytokines, IgG and IgM in all groups were not significantly different. Sensitizing antibody test showed that the fluorescence intensity of sensitized group significantly increased as compared with normal group, whereas fluorescence intensity of CTLA4Ig or/and anti-CD154 treated groups significantly decreased as compared with sensitized group (P < 0.01) . It is concluded that blocking the B7/CD28 or/and CD40/CD154 co-stimulatory signal can inhibit the cellular and humoral immune function, whereas blocking these two signals together displays a synergistic effect.


Subject(s)
Animals , Male , Mice , B7-1 Antigen , Metabolism , Bone Marrow Transplantation , CD28 Antigens , Metabolism , CD40 Antigens , Metabolism , CD40 Ligand , Metabolism , Immune Tolerance , Allergy and Immunology , Mice, Inbred BALB C , Mice, Inbred C57BL , Signal Transduction , Transplantation, Homologous
13.
Article in Chinese | WPRIM | ID: wpr-337279

ABSTRACT

<p><b>OBJECTIVE</b>To explore effects and action mechanism of warm moxibustion on regulation of blood lipids and anti-atherosclerosis.</p><p><b>METHODS</b>Forty-one male Japanese big-ear white rabbits were randomly divided into a blank group (10 rabbits), a model group (10 rabbits), a moxibustion group (10 rabbits) and a medication group (11 rabbits). Normal diet was applied in the blank group while high-cholesterol diet combined with injection of bovine serum albumin were applied in the rest groups to establish rabbit model of atherosclerosis. After establishment, the model group was not intervened and warm moxibustion was applied in the moxibustion group at "Zusan-li" (ST 36) and "Shenque" (CV 8), 10 min per acupoint per day for continuous 4 weeks. The medication group was treated with intragastric administration of lovastatin capsule (3.6 mg/kg) for continuous 4 weeks. The level of blood lipids, such as total cholesterol (TC), triglyceride (TG), and content of CD40 ligand (CD40L), soluble CD40 ligand (sCD40L) and expression of nuclear factor NF-kappaB were tested after 4 weeks.</p><p><b>RESULTS</b>Compared with the model group, the moxibustion group and medication group could effectively reduce the contents of TC and low density lipoprotein (all P < 0.05), lower the level of sCD40L [(8.310 +/- 1.221) ng/mL in the model group, (7.097 +/- 0.846) ng/mL in the moxibustion group and (7.354 +/- 0.631) ng/mL in the medication group], reduce expression of CD40L [(0.235 +/- 0.179) mm2 in the model group, (0.072 +/- 0.079) mm2 in the moxibustion group and (0.039 +/- 0.015) mm2 in the medication group] and NF-kappaB [(0.145 +/- 0.052)mm2 in the model group, (0.052 +/- 0.012) mm2 in the moxibustion group and (0.036 +/- 0.013) mm2 in the medication group], indicating the significant difference (P < 0.05, P < 0.001). There was no statistical difference between the moxibustion group and medication group (all P > 0.05).</p><p><b>CONCLUSION</b>The warm moxibustion has great effect on regulation of blood lipids and anti-atherosclerosis, in which lowering expression of CD40-CD40L could be one of possible mechanisms to take effect of anti-atherosclerosis.</p>


Subject(s)
Animals , Humans , Male , Rabbits , Atherosclerosis , Blood , Therapeutics , CD40 Antigens , Blood , CD40 Ligand , Blood , Lipids , Blood , Moxibustion , Methods
14.
Article in Chinese | WPRIM | ID: wpr-264936

ABSTRACT

This research was aimed to explore the effects of blocking B7/CD28 and CD40/CD154 co-stimulatory signals on engraftment of hematopoietic stem cell in the sensitized recipient so as to provide the experimental evidence for the treatment of sensitized recipient's immune rejection after clinical allogeneic hematopoietic stem cell transplantation (HSCT). The BALB/c mice were divided into 4 groups: (1)mice sensitized on 7 day before transplant; (2)mice were sensitized on 7 day before transplant, and injected CTLA4Ig+anti-CD154 applied; (3)normal mice injected by corresponding isotype control IgG of CTLA4Ig and anti-CD154; (4)normal blank control mice. Each group had 15 mice. On day 0, mice of each group were irradiated lethally 8 Gy by linear accelerator, and the bone marrow cells of C57BL/6 labeled by fluorescence staining were injected via the tail vein. The fluorescent cell level in peripheral blood and organ tissue at different time points were detected by flow cytometry (FCM) for homing assessment. Survival rates and hematopoietic reconstitution were also monitored and recorded. The results showed that application of CTLA4Ig anti-CD154 could promote implantation of allogeneic HSC in sensitized recipients, induce the immune tolerance, prolong their survival time and accelerate the hematopoietic reconstitution within 28 days, compared with the sensitized group. It is concluded that applying CTLA4Ig and anti-CD154 can enhance the engraftment of HSCT and induce immune tolerance in the sensitized recipient after allogeneic HSCT and accelerate the hematopoietic reconstitution.


Subject(s)
Animals , Male , Mice , Abatacept , B7 Antigens , CD28 Antigens , CD40 Antigens , CD40 Ligand , Graft Rejection , Hematopoietic Stem Cell Transplantation , Immune Tolerance , Immunoconjugates , Pharmacology , Mice, Inbred BALB C , Mice, Inbred C57BL , Transplantation, Homologous
15.
Article in Chinese | WPRIM | ID: wpr-289542

ABSTRACT

<p><b>OBJECTIVE</b>To study the association between two single nucleotide polymorphisms (rs4810485 and rs1535045 in CD40 gene) and Kawasaki disease (KD) in Han Chinese children.</p><p><b>METHODS</b>A case-control study was performed on 184 children with KD and 206 normal controls. The polymorphisms of two SNPs in CD40 gene were detected using PCR-RFLP.</p><p><b>RESULTS</b>There were no significant differences in the genotype distribution and allele frequency of SNP rs4810485 in CD40 gene between the KD and normal groups (P>0.05). The genotype distribution of SNP rs1535045 in CD40 gene in the KD group was significantly different from the control group (P<0.05). T allele of SNP rs1535045 was shown as a risk factor for development of KD (OR=1.592, 95%CI: 1.182-2.144, P=0.004). There were no association between the polymorphisms of the two SNPs and coronary artery lesions (P>0.05).</p><p><b>CONCLUSIONS</b>SNP rs1535045 may be associated with the development of KD in Han Chinese children, while SNP rs4810485 may not.</p>


Subject(s)
Child , Child, Preschool , Female , Humans , Infant , Male , CD40 Antigens , Genetics , Case-Control Studies , Coronary Artery Disease , Genetics , Mucocutaneous Lymph Node Syndrome , Genetics , Polymorphism, Single Nucleotide
16.
Article in Chinese | WPRIM | ID: wpr-332747

ABSTRACT

CD40 and its receptor CD40L are a very important pair of co-stimulating molecule in immune response, which have extensive biological effects. After stimulating CD40 signal, it can exert corresponding function through MAPK (JNK, ERK, p38) pathway, PI3K cascade, as well as NF-κB and STAT. The CD40 signal is closely related to tumor immunity, this moleculer has already become targeted-molecule for cancer treatment. Recently, there have been many anti-CD40 monoclonal antibodies displaying good anti-cancer effect, among which CHIR-12.12, SGN-40 and CP-870, 893 developed rapidly and successively have entered clinical research stage. This review focuses the status of anti-CD40 monoclonal antibody, including distribution of CD40, physiological function of CD40, CD40 and tumor immunity, anti-CD40 monoclonal antibodies and so on.


Subject(s)
Animals , Humans , Antibodies, Monoclonal , CD40 Antigens , Allergy and Immunology , Neoplasms
17.
Chinese Journal of Pathology ; (12): 819-823, 2013.
Article in Chinese | WPRIM | ID: wpr-288199

ABSTRACT

<p><b>OBJECTIVE</b>To study the expression of CD40 in diffuse large B-cell lymphoma (DLBCL) and its relationship with various clinical parameters, pathologic findings and prognostic data.</p><p><b>METHODS</b>The clinical information of 87 patients with DLBCL diagnosed in Jilin Province Cancer Hospital during the period from January, 2008 to october, 2012 was retrospectively reviewed. Immunohistochemical study using SP technique for CD40 was carried out. The correlation between clinicopathologic findings, CD40 expression and survival data was analyzed using statistical software.</p><p><b>RESULTS</b>Cases of CD40-positive DLBCL were characterized by lower age group, early clinical stage, less extranodal involvement, lower IPI index and lower ECOG score. However, there was no significant correlation between gender of patients and site of involvement (P = 0.141 and 0.729). The overall survival of patients with CD40-positive DLBCL was significantly higher than that in patients with CD40-negative DLBCL. One-way analysis of variance showed that the prognosis of DLBCL was closely associated with CD40 expression, age of patients, ECOG score, IPI index, extranodal involvement and LDH level (P < 0.05, respectively). Stratified analysis showed that CD40-positive DLBCL carried a better prognosis, irrespective of other immunophenotyping results. COX model multivariate analysis showed that the expression of CD40 closely correlated with other immunophenotyping results, ECOG score, clinical staging, treatment regimen and prognosis (P < 0.05).</p><p><b>CONCLUSION</b>The expression of CD40 is a favorable prognostic indicator in patients with DLCBL.</p>


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Age Factors , Antibodies, Monoclonal, Murine-Derived , Therapeutic Uses , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , CD40 Antigens , Metabolism , Cyclophosphamide , Therapeutic Uses , Doxorubicin , Therapeutic Uses , Follow-Up Studies , Immunophenotyping , Lactate Dehydrogenases , Metabolism , Lymphoma, Large B-Cell, Diffuse , Drug Therapy , Metabolism , Pathology , Neoplasm Staging , Prednisone , Therapeutic Uses , Retrospective Studies , Survival Rate , Vincristine , Therapeutic Uses
18.
Chinese Medical Journal ; (24): 2934-2937, 2013.
Article in English | WPRIM | ID: wpr-263554

ABSTRACT

<p><b>BACKGROUND</b>Traumatic brain injury (TBI) is a major cause of death and disability in children and young adults worldwide. Therefore, we investigated the role of AG490 in regulating brain oedema, expression of CD40 and neurological function after TBI.</p><p><b>METHODS</b>Sprague Dawley rats (n = 240) were randomly divided into a sham operation group, TBI+saline group and TBI+AG490 (JAK/STAT inhibitor) group. Members of each group were euthanized at 6, 12, 24 or 72 hours after injury. Neurological severity score (NSS) was used to evaluate the severity of neurological damage. Brain water was quantitated by wet/dry weight method. The expression of CD40 was assessed by flow cytometry.</p><p><b>RESULTS</b>In both the TBI+saline group and the TBI+AG490 group, the brain water content was elevated after TBI, reached a peak at 24-hour and remained high for the rest of the period investigated; the expression of CD40 reached a peak 24 hours after TBI; the NSS was elevated after TBI and then decreased after 6 hours. Elevations in the level of CD40, degree of brain edema and NSS after TBI were significantly reduced in TBI+AG490 group.</p><p><b>CONCLUSION</b>Inhibition of the JAK/STAT signalling pathway reduces brain oedema, decreases the expression of CD40 and exerts neuroprotective effects after TBI.</p>


Subject(s)
Animals , Male , Rats , Brain Edema , Metabolism , Brain Injuries , Drug Therapy , CD40 Antigens , Flow Cytometry , Janus Kinases , Metabolism , Neuroprotective Agents , Therapeutic Uses , Rats, Sprague-Dawley , STAT Transcription Factors , Metabolism , Tyrphostins , Therapeutic Uses
19.
Article in Chinese | WPRIM | ID: wpr-814656

ABSTRACT

CD40/CD40L is a pair of complementary transmembrane glycoproteins, expressed on immune cells, endothelial cells, smooth muscle cells, platelets and other cells involved in regulation of immunity, inflammation, coagulation and other pathophysiologic states. A large number of researches have demonstrated that, when atherosclerosis occurs, CD40L ligates CD40; subsequently CD40 is activated and stimulates downstream signaling pathways, including nuclear factor-kappaB, with consequent up-regulation of proinflammatory and proatherogenic genes. Thus it plays an important role in the occurrence, development and plaque-rupture of atherosclerosis. CD40/CD40L is a bridge between immunity, inflammation, and a hypercoagulable state, and may be an important target for prevention and treatment of cardiovascular disease.


Subject(s)
Animals , Humans , Atherosclerosis , Genetics , CD40 Antigens , Genetics , CD40 Ligand , Genetics , Immunity , Physiology , Inflammation , NF-kappa B , Metabolism , Polymorphism, Genetic , Thrombophilia
20.
Article in English | WPRIM | ID: wpr-233098

ABSTRACT

As CD40 transduces activation signals involved in inflammatory and immune disorders, we explored the expression and response to CD40 engagement in human glioma cell lines in this study. The CD40 expression in BT-325 and U251 cells was flow cytometrically detected. The cells were incubated with srhCD40L for 72 h to assess its effects on cell growth in vitro. TNF-α expression was quantified by real-time PCR, and protein expression was analyzed by ELISA. The I-κb mRNA was detected by RT-PCR. I-κB expression decreased after stimulation with 1 μg/mL srhCD40L, but it was upregulated after the cells were pretreated with CD40 antibody. srhCD40L significantly inhibited the proliferation of the CD40+ human glioma cells. The stimulation of CD40+ glioma cells with soluble CD40L (CD154) up-regulated the expression of TNF-α at both mRNA and protein levels. We are led to conclude that CD40L/CD40 could inhibit human glioma cells through I-κb signaling pathway. Interferon-γ can augment CD40 expression and the inhibitory effect of CD40 ligand on cell growth in vitro. These results suggest that srhCD40L may benefit the therapy strategy of glioma.


Subject(s)
Humans , CD40 Antigens , Metabolism , CD40 Ligand , Metabolism , Cell Proliferation , Cells, Cultured , Glioma , Genetics , Metabolism , Pathology , NF-kappa B , Metabolism , Signal Transduction , Physiology , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL